Search results

  1. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

  2. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  3. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced

  4. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults

  5. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

  6. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

  7. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

  8. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell

  9. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive

  10. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for

  11. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

  12. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    Evidence-based recommendations on axicabtagene ciloleucel therapy (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma

  13. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up

  14. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in

  15. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

  16. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

  17. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

  18. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

  19. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

  20. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2

  21. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

  22. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

  23. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been

  24. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced

  25. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

    Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults

  26. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that

  27. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who

  28. Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

    Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic